Head to Head Contrast: Zhongchao (NASDAQ:ZCMD) versus Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH) and Zhongchao (NASDAQ:ZCMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

1.7% of Zhongchao shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 28.6% of Zhongchao shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Nyxoah and Zhongchao, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
Zhongchao	1	0	0	0	1.00

Nyxoah currently has a consensus target price of $5.96, indicating a potential upside of 322.87%. Given Nyxoah’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Nyxoah is more favorable than Zhongchao.

Profitability

This table compares Nyxoah and Zhongchao’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Zhongchao	N/A	N/A	N/A

Risk and Volatility

Nyxoah has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, Zhongchao has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nyxoah and Zhongchao”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33 million	4.82	-$101.92 million	($2.48)	-0.57
Zhongchao	$11.38 million	0.13	-$6.31 million	N/A	N/A

Zhongchao has higher revenue and earnings than Nyxoah.

Summary

Zhongchao beats Nyxoah on 7 of the 12 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.